SGLT2 Inhibitors Market Size & Insights

According to MarkNtel Advisors study The future of SGLT2 Inhibitors Market size was valued at around USD 18.41 billion in 2024 and is projected to reach USD 30.34 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 8.68% during the forecast period, i.e., 2025-30. 

What are the Key Driver in the SGLT2 Inhibitors Market?

High Prevalence of Chronic Diseases – The market demand is driven by the high burden of chronic disorders globally, especially cardiovascular diseases, chronic disorders, and type 2 diabetes. For instance, as per the International Diabetes Federation (2021), there were over 540 million adult patients with type 2 diabetes globally, which is further expected to reach more than 640 million. Similarly, chronic kidney disease (CKD) is also highly prevalent globally, accounting for more than 840 million individuals all around the world. Also, more than 65 million individuals experience heart failure globally.

These are increasing the demand for advanced medication such as the SGLT2 Inhibitors, which can inhibit the action of the SGLT2 protein and are highly effective in overcoming these diseases, thus increasing market growth. It has led to the expansion of the SGLT2-inhibitor-based drugs' active pharmaceutical ingredient plants (API) worldwide. For instance, there are about 40-50 API plants globally that are specific to SGLT2 inhibitors.

Boost Your Company's Decisions by Getting a Free Sample Right Away- https://www.marknteladvisors.com/query/request-sample/sglt2-inhibitors-market.html

What are the Key Segments in the SGLT2 Inhibitors Market?

The SGLT2 Inhibitors is categorized into notable segments, which help in understanding the structure, dynamics, and opportunities within the market. These segments are typically based on:

• By Drug Type
  • Jardiance (empagliflozin) - Market Size & Forecast 2020-2030, USD Million
  • Farxiga (dapagliflozin) - Market Size & Forecast 2020-2030, USD Million
  • Invokana (canagliflozin) - Market Size & Forecast 2020-2030, USD Million
  • Inpefa (sotagliflozin) - Market Size & Forecast 2020-2030, USD Million
  • Qtern (dapagliflozin/saxagliptin) - Market Size & Forecast 2020-2030, USD Million
  • Others- Market Size & Forecast 2020-2030, USD Million
• By Application
  • Type 2 Diabetes- Market Size & Forecast 2020-2030, USD Million
  • Cardiovascular- Market Size & Forecast 2020-2030, USD Million
  • Chronic Kidney Disease (CKD) - Market Size & Forecast 2020-2030, USD Million
  • Others- Market Size & Forecast 2020-2030, USD Million
• By End User
  • Hospital Pharmacies- Market Size & Forecast 2020-2030, USD Million
  • Retail Pharmacies- Market Size & Forecast 2020-2030, USD Million
  • Online Pharmacies- Market Size & Forecast 2020-2030, USD Million

View Full Report (All Data, In One Place): https://www.marknteladvisors.com/research-library/sglt2-inhibitors-market.html (Explore in-depth analyses, technological trends, and investment patterns.)

How does geographical analysis highlight in the SGLT2 Inhibitors market?

By Region

·       North America

·       South America

·       Europe

·       The Middle East & Africa

·       Asia-Pacific

Who are the Key Players in SGLT2 Inhibitors Market?

·       Astellas

·       AstraZeneca

·       Boehringer Ingelheim International

·       Bristol-Myers Squibb Company

·       Eli Lilly and Company

·       Glenmark Pharmaceuticals

·       Johnson & Johnson (Janssen Pharmaceuticals)

·       Lexicon Pharmaceuticals

·       Lupin Limited

·       Merck

·       Sanofi

·       TheracosBio

Talk to Our Industry Analyst: https://www.marknteladvisors.com/query/talk-to-our-consultant/sglt2-inhibitors-market.html (Get personalized insights into company strategies and regional market dynamics.)

SGLT2 Inhibitors Market News

2024: Eli Lilly and Company launched a new combination therapy, bringing together its SGLT2 inhibitor Jardiance (empagliflozin) with a GLP-1 agonist. This new treatment helps improve blood sugar control and supports weight loss in people with type 2 diabetes, offering a more effective option for managing the condition. 

Key pillars of the research methodology include:

Scope & Research Design – Clearly defined objectives with tailored qualitative and quantitative methods, backed by precise timelines and budgets.

Sample Selection & Data Collection – Representative samples achieved through proven techniques like random and stratified sampling, supported by reliable tools such as surveys, interviews, and observations.

Data Analysis & Validation – Rigorous cleaning, advanced statistical modeling, and thematic analysis ensure accuracy, reliability, and minimal bias.

Forecasting & Finalization – Predictive modeling and time-series analysis anticipate future market behaviors, presented through insightful reports with charts, graphs, and strategic recommendations.

"Our methodology reflects the trust businesses place in us. By combining innovation with precision, we deliver not just numbers, but clarity and direction for decision-makers worldwide," said a spokesperson for MarkNtel Advisors.

Why This MarkNtel Advisors Research Report:

• In-depth Market Analysis: Understand trends and dynamics shaping growth.
• Segmented Insights: Target specific segments for focused strategies.
• Geographical Performance: Assess market opportunities by geographic area.
• Emerging Technologies: Discover advancements like AI integration.
• Risk Identification: Pinpoint challenges to inform strategic planning.
• Future Forecasts: Prepare for market changes with actionable projections.

Gain exclusive access to our comprehensive insights on the Future of SGLT2 Inhibitors Market. With tailored licensing options, including Mini Report Pack, Excel Data Pack, Single User, Multiuser, and Enterprise Packs, our research empowers organizations to navigate dynamic market trends effectively.

Select a License That Matches Your Business Requirements with Instant Offer - https://www.marknteladvisors.com/pricing/sglt2-inhibitors-market.html

About Us:

MarkNtel Advisors is a globally recognized market research and consulting firm delivering intelligence across the healthcare industry, spanning pharmaceuticals, medical devices, healthcare IT, and biotechnology. Our analysts combine domain expertise with innovation tracking to help healthcare organizations improve efficiency and patient outcomes. Through Consulting Services, we assist clients in interpreting insights, designing go-to-market strategies, and adapting to regulatory changes, fostering sustainable growth in the evolving global healthcare ecosystem.

Reach Us:

MarkNtel Advisors

Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India

Contact No: +91 8719999009

Email: sales@marknteladvisors.com

Visit our Website: https://www.marknteladvisors.com

Trending Blogs - https://www.marknteladvisors.com/blogs